Fine Foods & Pharmaceuticals N.T.M. (BIT: FF) stock: the official figures
Fine Foods & Pharmaceuticals N.T.M. ("FINE FOODS & PHARMACEUTICALS N.T.M. S.P.A.") is listed on the Milan stock exchange under the ticker FF and belongs to the consumer staples sector. In fiscal 2025 it reported revenue of €253.5m and a net profit of €10.1m, according to the annual accounts it filed with the regulator.
Identifiers for Fine Foods & Pharmaceuticals N.T.M.: ISIN IT0005215329 · LEI 8156009111DEE8553765.
Fiscal 2025 figures
| Item | 2025 | 2024 | Change |
|---|---|---|---|
| Revenue | €253.5m | €245.1m | +3.4% |
| Operating profit | €16.4m | €14.6m | +12.1% |
| Net profit | €10.1m | €8.2m | +23.8% |
| Earnings per share | €0.41 | €0.32 | +28.1% |
| Operating margin | 6.5% | 6.0% | +0.5 pts |
| Net margin | 4.0% | 3.3% | +0.7 pts |
| Total assets | €280.0m | €242.6m | +15.4% |
| Equity | €134.2m | €132.1m | +1.6% |
| Cash | €38.9m | €19.2m | +102.4% |
| Operating cash flow | €31.8m | €45.9m | −30.7% |
Margins are calculated from the filed figures: operating profit and net profit over revenue.
5 fiscal years
| Fiscal year | Revenue | Operating profit | Net profit | Earnings per share | Document |
|---|---|---|---|---|---|
| 2025 | €253.5m | €16.4m | €10.1m | €0.41 | Annual report |
| 2024 | €245.1m | €14.6m | €8.2m | €0.32 | Annual report |
| 2023 | €252.9m | €1.1m | −€3.5m | −€0.14 | Annual report |
| 2022 | €208.3m | −€1.0m | −€9.5m | −€0.37 | Annual report |
| 2021 | €195.2m | €5.0m | −€1.4m | −€0.06 | — |
The full income statement, balance sheet and cash flow statement are in the annual accounts of Fine Foods & Pharmaceuticals N.T.M.. Year by year: revenue, net income and dividends paid.
Dividends
In fiscal 2025, Fine Foods & Pharmaceuticals N.T.M. paid €3.4m in dividends, 33.9% of its net profit, according to its cash flow statement.
| Fiscal year | Dividends paid | Share of net profit |
|---|---|---|
| 2025 | €3.4m | 33.9% |
| 2024 | €2.9m | 36.0% |
| 2023 | €2.5m | — |
| 2022 | €3.9m | — |
| 2021 | €3.2m | — |
Cash paid out as dividends during the fiscal year, including dividends to minority shareholders of subsidiaries when the company does not report them separately. It is not the dividend per share.
Frequently asked questions about Fine Foods & Pharmaceuticals N.T.M.
- How much did Fine Foods & Pharmaceuticals N.T.M. earn in fiscal 2025?
- Fine Foods & Pharmaceuticals N.T.M. reported a net profit of €10.1m for fiscal 2025, on revenue of €253.5m. The year before it reported a net profit of €8.2m.
- Does Fine Foods & Pharmaceuticals N.T.M. pay a dividend?
- In fiscal 2025, Fine Foods & Pharmaceuticals N.T.M. paid €3.4m in dividends, 33.9% of its net profit, according to its cash flow statement.
- What are the earnings per share of Fine Foods & Pharmaceuticals N.T.M.?
- They were €0.41 in fiscal 2025, compared with €0.32 the year before.
- Where is Fine Foods & Pharmaceuticals N.T.M. listed?
- Fine Foods & Pharmaceuticals N.T.M. is listed on the Milan stock exchange under the ticker FF and belongs to the consumer staples sector.
- What is the ISIN of Fine Foods & Pharmaceuticals N.T.M.?
- The ISIN of Fine Foods & Pharmaceuticals N.T.M. is IT0005215329, the international code that identifies its shares. Its LEI, the legal entity identifier, is 8156009111DEE8553765.
- Where do the figures for Fine Foods & Pharmaceuticals N.T.M. come from?
- From the report Fine Foods & Pharmaceuticals N.T.M. files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
The annual accounts come from the report Fine Foods & Pharmaceuticals N.T.M. files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year in the table links to its filing. Celsmar reads the tagged figures from the document and does not adjust them: if an item is not in the filing, it is not shown. More detail in data sources and, if you spot an error, in corrections. What Celsmar is and what it costs, in its fact sheet.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.